NCT01638936 - BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 3, 2012

Primary Completion Date

October 30, 2018

Study Completion Date

October 30, 2018

Conditions

Multiple Myeloma

Interventions

DRUG

BT062 , intravenous administration

Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone

Trial Locations (10)

10029

Mount Sinai Medical Center, New York

30322

Emory University Winship Cancer Institute, Atlanta

32224

Mayo Clinic, Jacksonville

33028

Memorial Healthcare System, Pembroke Pines

60637

The University of Chicago, Chicago

78229

University of Texas Health Science Center, San Antonio

90033

USC Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope, Duarte

02115

Dana-Farber Cancer Institute, Boston

07601

Hackensack University Medical Center, Hackensack